Elizabeth E Rogers1, Sonia L Bonifacio1, Hannah C Glass2, Sandra E Juul3, Taeun Chang4, Dennis E Mayock3, David J Durand5, Dongli Song6, Anthony J Barkovich7, Roberta A Ballard1, Yvonne W Wu8. 1. Department of Neonatology, UCSF Benioff Children's Hospital, San Francisco, California. 2. Department of Neonatology, UCSF Benioff Children's Hospital, San Francisco, California; Department of Neurology, UCSF Benioff Children's Hospital, San Francisco, California. 3. Department of Neonatology, University of Washington, Seattle, Washington. 4. Department of Neurology, Children's National Medical Center, Washington DC. 5. Department of Neonatology, Children's Hospital & Research Center Oakland, Oakland, California. 6. Department of Neonatology, Santa Clara Valley Medical Center, San Jose, California. 7. Department of Neurology, UCSF Benioff Children's Hospital, San Francisco, California. 8. Department of Neonatology, UCSF Benioff Children's Hospital, San Francisco, California; Department of Neurology, UCSF Benioff Children's Hospital, San Francisco, California. Electronic address: wuy@neuropeds.ucsf.edu.
Abstract
BACKGROUND: Erythropoietin is neuroprotective in animal models of neonatal hypoxic-ischemic encephalopathy. We previously reported a phase I safety and pharmacokinetic study of erythropoietin in neonates. This article presents the neurodevelopmental follow-up of infants who were enrolled in the phase I clinical trial. METHODS: We enrolled 24 newborns with hypoxic-ischemic encephalopathy in a dose-escalation study. Patients received up to six doses of erythropoietin in addition to hypothermia. All infants underwent neonatal brain magnetic resonance imaging (MRI) reviewed by a single neuroradiologist. Moderate-to-severe neurodevelopmental disability was defined as cerebral palsy with Gross Motor Function Classification System levels III-V or cognitive impairment based on Bayley Scales of Infant Development II mental developmental index or Bayley III cognitive composite score. RESULTS: Outcomes were available for 22 of 24 infants, at mean age 22 months (range, 8-34 months). There were no deaths. Eight (36%) had moderate-to-severe brain injury on neonatal MRI. Moderate-to-severe disability occurred in one child (4.5%), in the setting of moderate-to-severe basal ganglia and/or thalamic injury. Seven infants with moderate-to-severe watershed injury exhibited the following outcomes: normal (three), mild language delay (two), mild hemiplegic cerebral palsy (one), and epilepsy (one). All 11 patients with a normal brain MRI had a normal outcome. CONCLUSIONS: This study is the first to describe neurodevelopmental outcomes in infants who received high doses of erythropoietin and hypothermia during the neonatal period. The findings suggest that future studies are warranted to assess the efficacy of this new potential neuroprotective therapy.
BACKGROUND:Erythropoietin is neuroprotective in animal models of neonatal hypoxic-ischemicencephalopathy. We previously reported a phase I safety and pharmacokinetic study of erythropoietin in neonates. This article presents the neurodevelopmental follow-up of infants who were enrolled in the phase I clinical trial. METHODS: We enrolled 24 newborns with hypoxic-ischemicencephalopathy in a dose-escalation study. Patients received up to six doses of erythropoietin in addition to hypothermia. All infants underwent neonatal brain magnetic resonance imaging (MRI) reviewed by a single neuroradiologist. Moderate-to-severe neurodevelopmental disability was defined as cerebral palsy with Gross Motor Function Classification System levels III-V or cognitive impairment based on Bayley Scales of Infant Development II mental developmental index or Bayley III cognitive composite score. RESULTS: Outcomes were available for 22 of 24 infants, at mean age 22 months (range, 8-34 months). There were no deaths. Eight (36%) had moderate-to-severe brain injury on neonatal MRI. Moderate-to-severe disability occurred in one child (4.5%), in the setting of moderate-to-severe basal ganglia and/or thalamic injury. Seven infants with moderate-to-severe watershed injury exhibited the following outcomes: normal (three), mild language delay (two), mild hemiplegic cerebral palsy (one), and epilepsy (one). All 11 patients with a normal brain MRI had a normal outcome. CONCLUSIONS: This study is the first to describe neurodevelopmental outcomes in infants who received high doses of erythropoietin and hypothermia during the neonatal period. The findings suggest that future studies are warranted to assess the efficacy of this new potential neuroprotective therapy.
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: Yun Sil Chang; Dezhi Mu; Michael Wendland; R Ann Sheldon; Zinaida S Vexler; Patrick S McQuillen; Donna M Ferriero Journal: Pediatr Res Date: 2005-05-05 Impact factor: 3.756
Authors: Fernando F Gonzalez; Patrick McQuillen; Dezhi Mu; Yunsil Chang; Michael Wendland; Zinaida Vexler; Donna M Ferriero Journal: Dev Neurosci Date: 2007 Impact factor: 2.984
Authors: Sandra E Juul; Bryan A Comstock; Patrick J Heagerty; Dennis E Mayock; Amy M Goodman; Stephanie Hauge; Fernando Gonzalez; Yvonne W Wu Journal: Neonatology Date: 2018-03-07 Impact factor: 4.035
Authors: Monica E Lemmon; Renee D Boss; Sonia L Bonifacio; Audrey Foster-Barber; A James Barkovich; Hannah C Glass Journal: J Child Neurol Date: 2016-12-20 Impact factor: 1.987
Authors: Robin K Ohls; Daniel C Cannon; John Phillips; Arvind Caprihan; Shrena Patel; Sarah Winter; Michael Steffen; Ronald A Yeo; Richard Campbell; Susan Wiedmeier; Shawna Baker; Sean Gonzales; Jean Lowe Journal: Pediatrics Date: 2016-02-15 Impact factor: 7.124
Authors: Nienke Wagenaar; Caroline G M de Theije; Linda S de Vries; Floris Groenendaal; Manon J N L Benders; Cora H A Nijboer Journal: Pediatr Res Date: 2017-11-01 Impact factor: 3.756